AR051248A1 - Derivados de 3-arilamino piridina - Google Patents

Derivados de 3-arilamino piridina

Info

Publication number
AR051248A1
AR051248A1 ARP050104369A ARP050104369A AR051248A1 AR 051248 A1 AR051248 A1 AR 051248A1 AR P050104369 A ARP050104369 A AR P050104369A AR P050104369 A ARP050104369 A AR P050104369A AR 051248 A1 AR051248 A1 AR 051248A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
heterocyclyl
aryl
cr4r5
Prior art date
Application number
ARP050104369A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR051248A1 publication Critical patent/AR051248A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

Estos compuestos son los inhibidores MEK y son utiles en el tratamiento de las enfermedades proliferativas tales como el cáncer, restenosis y la inflamacion. También revelados en la presente está el uso de tales compuestos en el tratamiento de las enfermedades hiperprolifertivas en los mamíferos, especialmente los seres humanos y las composiciones farmacéuticas que contienen tales compuestos. Reivindicacion 1: Un compuesto de formula (1), una sal farmacéuticamente aceptable, un solvato o una prodroga de la misma, en donde: R1, R2, R9, R10, R11, R12, R13 y R14 están independientemente seleccionadas desde el hidrogeno, halogeno, ciano, nitro, azido, -OR3, -NR4C(O)OR6, -OC(O)R3, -NR4C(O)jR6, -S(O)jNR3R4, S(O)jNR4C(O)R3, -C(O)NR4S(O)jR6, S(O)jR6, -NR4C(O)R3, -C(O)NR3R4, NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4 y C1-10 alquilo, C2-10 alquenilo, C1-10 alquinilo, C3-10 cicloalquilo, C3-10 cicloalquiloalquilo, -S(O)jC1-6alquilo, S(O)j(CR4R5)m-arilo, arilo, ariloalquilo, heteroarilo, heteroariloalquilo, heterociclilo, heterocicliloalquilo, -O(CR4R5)m-arilo, -NR4(CR4R5)m-arilo, -O(CR4R5)m-heteroarilo, NR4(CR4R5)m, heteroarilo, -O(CR4R5)m-heterociclilo, -NR4(CR4R5)m-heterociclilo y -SC1-2-alquilo sustituido con 1 a 5 F, donde cada uno alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo son sustituido o no sustituido; R3 está seleccionado de hidrogeno, trifluormetil, C1-10 alquilo, C2-10 alquenilo, C2-10 alquinilo, C3-10 cicloalquilo, C3-10 cicloalquiloalquilo, ariloalquilo, heteroarilo, heteroariloalquilo, heterociclilo, y heterocicliloalquilo, donde cada uno de alquilo, alquenilo, alquinilo, cicloalquilo, heteroarilo y heterociclilo está sustituido o no sustituido; o el arilo que está no sustituido o sustituido con 1 a 5 grupos independientemente seleccionados del oxo, halogeno, nitro, CF3, CHF2, CH2F, OCF3, OCHF2, OCH2F, azido, NR'SO2R'''' SO2NR'', C(O)R', C(O)OR', OC(O)R', NR'C(O)OR'''', NR'C(O)R'', C(O9NR'R'', SR'''', S(O)R'''', SO2R', NR'R'', NR'C(O)NR''R''', NR'C(NCN)NR''R''', OR', arilo, heteroarilo, ariloalquilo, heteroariloalquilo, heterociclilo, y heterocicloalquilo; R4 está seleccionado de hidrogeno o C1-6 alquilo donde el alquilo pueda estar sustituida o no sustituido; o R3 y R4 pueden ser tomadas juntas con el átomo al que están unidos para formar un anillo de heteroarilo o heterocíclico de 4 a 10 miembros, cada uno que está sustituido o no sustituido; R5 está seleccionada del hidrogeno o C1-6 alquilo donde el alquilo puede estar sustituido o no sustituido; o R4 y R5 pueden ser tomadas juntas con el átomo al que están unidos para formar un anillo de 4 a 10 miembros carbocíclico, heteroarilo o heterocíclico, cada uno está sustituido o no sustituido; R6 está seleccionada de trifluormetil; y C1-10 alquilo, C3-10 cicloalquilo, arilo, ariloalquilo, heteroarilo, heteroariloalquilo, heterociclilo, y heterocicliloalquilo, donde cada uno alquilo, cicloalquilo, arilo, heteroarilo y heterociclilo sustituido o no sustituido; R', R'' y R''' están independientemente seleccionadas desde el hidrogeno, C1-4 alquilo, C2-4 alquenilo, arilo y ariloalquilo; R'''' está seleccionada del C1-4 alquilo, C1-4 alquenilo, arilo y ariloalquilo; W está seleccionado de heteroarilo que contiene de 1-4 heteroátomos o heterociclilo que contiene de 1-4 heteroátomos cada una que está no sustituido o sustituido por 1 a 5 sustituyentes ZR15; o W está -C(O)OR15, -C(O)NR4R5, -C(O)NR4OR15, -C(O)C3- 10cicloalquilo, C(O)(heterociclilo, S(O)jNR4R15, S(O)jNR4OR15, -S(O)jNR4C(O)R15, C(O)NR4S(O)jR6, -C(O)NR3NR4R15, -C(O)C(O)R15, -C(O)CR'R''C(O)R15, -NR'R'', NR'C(O)R', -NR'S(O)jR', -NRC(O)NR'R'', NR'S(O)jNR'R'', o -C(O)NR4NR4C(O)R15; y cuando W está C(O)OH, entonces R1, R2, R12, R13 y R14 están independientemente seleccionadas del hidrogeno, halogeno, ciano, nitro, azido, -NR4C(O)OR6, -OC(O)R3, -NR4S(O)jR6, S(O)jNR3R4, -S(O)jNR4C(O)R3, -C(O)NR4S(O)jR6, S(O)jR6, -NR4C(O)R3, NR5C(O)NR3R4, - NR5C(NCN)NR3R4 y C1-10 alquilo, C2-10 alquenilo, C2-10 alquinilo, C3-10 cicloalquilo, C3-10 cicloalquilalquilo, -S(O)jC1-6alquilo, S(O)j(CR4R5)m-arilo, arilo, ariloalquilo, heteroarilo, heteroariloalquilo, heterociclilo, heterocicliloalquilo, - O(CR4R5)m-arilo, -NR4(CR4R5)m-arilo, -O(CR4R5)m-heteroarilo, NR4(CR4R5)m, heteroarilo, -O(CR4R5)m-heterociclilo, -NR4(CR4R5)m-heterociclilo y -SC3-10-alquilo sustituido con 1 a 5 F, donde cada uno alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo son sustituido o no sustituido; NR33R44, C(O)NR3R44, o OR33, donde R33 está seleccionado de hidrogeno, CF3, CHF2, CH2F, C2-10 alquilo, C2-10 alquenilo, C2-10 alquinilo, C3-10 cicloalquilo, C3-10 cicloalquiloalquilo, ariloalquilo, heteroarilo, heteroariloalquilo, heterociclilo, y heterocicliloalquilo, donde cada uno alquilo, alquenilo, alquinilo, cicloalquilo, heteroarilo y el heterociclilo está sustituido o no sustituido, y R44 está seleccionado de hidrogeno, CF3, CHF2, CH2F y C2-6 alquilo; Z es una union, NR16, O, NR16SO2 o S; R15 está independientemente seleccionada del hidrogeno, trifluormetil C1-10 alquilo, C2-10 alquenilo, C2-10 alquinilo, C3-10 cicloalquilo, C2-10 cicloalquilalquilo, arilo, ariloalquilo, heteroarilo, heteroariloalquilo, heterociclilo, y heterocicloalquilo, donde cada uno alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo está sustituido o no sustituido; R16 está seleccionado de hidrogeno o C1-10 alquilo, o R15 y R16 desde junto con un anillo de 4 a 10 miembros cíclico con 1 o 2 N átomos y opcionalmente un átomo O, dicho anillo que está sustituido o no sustituido; X está N o N -> O; m es 0, 1, 2, 3, 4 o 5; y j es 1 o 2, con la salvedad que el ácido 3-(4-metooxi-fenilamino)-nicotínico, metil éster del ácido 3-fenilaminonicotínico, el ácido 2,3,6-trifluor-5-fenilamino-nicotínico y el metil éster del ácido 3-oxo-3-(3-fenilamino-piridin-4-il)-propionico no están incluidos.
ARP050104369A 2004-10-20 2005-10-19 Derivados de 3-arilamino piridina AR051248A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04024967 2004-10-20

Publications (1)

Publication Number Publication Date
AR051248A1 true AR051248A1 (es) 2007-01-03

Family

ID=34927054

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104369A AR051248A1 (es) 2004-10-20 2005-10-19 Derivados de 3-arilamino piridina

Country Status (22)

Country Link
US (4) US7956191B2 (es)
EP (1) EP1802579B1 (es)
JP (1) JP5214971B2 (es)
KR (1) KR101318012B1 (es)
CN (1) CN101065358B (es)
AR (1) AR051248A1 (es)
AU (1) AU2005298932B2 (es)
BR (1) BRPI0518192B8 (es)
CA (1) CA2582247C (es)
CY (1) CY1114861T1 (es)
DK (1) DK1802579T3 (es)
EA (1) EA013212B1 (es)
ES (1) ES2444866T3 (es)
HK (1) HK1107347A1 (es)
MX (1) MX2007004781A (es)
NO (1) NO339639B1 (es)
PL (1) PL1802579T3 (es)
PT (1) PT1802579E (es)
SI (1) SI1802579T1 (es)
UA (1) UA94571C2 (es)
WO (1) WO2006045514A1 (es)
ZA (1) ZA200703912B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802579E (pt) 2004-10-20 2014-02-17 Merck Serono Sa Derivados da 3-arilaminopiridina
CA2622755C (en) * 2005-10-07 2017-01-31 Exelixis, Inc. Azetidines as mek inhibitors
EA200802050A1 (ru) 2006-04-19 2009-04-28 Лаборатуар Сероно Са Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
JP2010500994A (ja) * 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
ES2703723T3 (es) 2006-12-14 2019-03-12 Exelixis Inc Métodos para usar inhibidores de MEK
ES2319596B1 (es) * 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
WO2008124085A2 (en) * 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
SI2307376T1 (sl) * 2008-08-04 2016-02-29 Merck Patent Gmbh Nove spojine fenilamino izonikotinamida
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
BR112012003284A8 (pt) * 2009-08-11 2016-05-17 Allergan Inc isotiozóis para tratar condições dos olhos
MX360932B (es) 2010-02-25 2018-11-21 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
EA030276B1 (ru) 2010-03-09 2018-07-31 Дана-Фарбер Кэнсер Инститьют, Инк. Способы идентификации страдающих раком пациентов и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
WO2012007861A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
ES2532357T3 (es) * 2010-07-12 2015-03-26 Pfizer Limited Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
WO2012007869A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
ES2603032T3 (es) 2010-07-15 2017-02-23 Bayer Intellectual Property Gmbh Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
CN102718702B (zh) * 2011-03-31 2015-01-07 中国人民解放军军事医学科学院毒物药物研究所 氨基吡啶类衍生物及其用途
SG11201406199TA (en) 2012-04-06 2014-10-30 Sanofi Sa Methods for treating cancer using pi3k inhibitor and mek inhibitor
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
BR112014029838A2 (pt) * 2012-05-30 2017-06-27 Merck Patent Gmbh formas no estado sólido de n-((s)-2,3-di-hidróxi-propil)-3-(2-flúor-4-iodo-fenilamino)- isonicotinamida
SG11201501923WA (en) 2012-09-13 2015-04-29 Hoffmann La Roche 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders
EP2909188B1 (en) * 2012-10-12 2018-03-07 Exelixis, Inc. Novel process for making compounds for use in the treatment of cancer
BR112015009777A2 (pt) * 2012-10-31 2017-07-11 Fujifilm Corp derivado de amina ou sal do mesmo
EP2752191A1 (en) * 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
EP2963114B1 (en) 2013-02-27 2018-12-12 Daiichi Sankyo Company, Limited Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway
CN104788365B (zh) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 异烟酰胺衍生物、其制备方法及应用
KR20160138756A (ko) * 2015-05-26 2016-12-06 연세대학교 산학협력단 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법
US10179132B2 (en) 2015-05-26 2019-01-15 Industry-Academic Cooperation Foundation, Yonsei University Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20240014585A (ko) 2016-03-04 2024-02-01 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
JP6663509B2 (ja) 2016-11-25 2020-03-11 ジェヌーヴ インク． 神経幹細胞の分化促進用及び保護用の組成物、並びにそれを利用して神経再生を誘導する方法
US11186554B2 (en) 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
KR101833412B1 (ko) 2017-07-24 2018-02-28 연세대학교 산학협력단 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법
WO2019040380A1 (en) 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. BENZOSULFONYL COMPOUNDS
CA3084648A1 (en) 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
CN111867594A (zh) 2018-03-19 2020-10-30 大鹏药品工业株式会社 包含烷基硫酸钠的药物组合物
WO2019183385A1 (en) * 2018-03-22 2019-09-26 University Of Rochester Mapk/erk inhibition for ovarian and other cancers
US11661403B2 (en) 2018-05-16 2023-05-30 Vivace Therapeutics, Inc. Oxadiazole compounds
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
WO2021206167A1 (ja) 2020-04-10 2021-10-14 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
AU2021376892A1 (en) 2020-11-16 2023-06-29 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
EP4263501A1 (en) * 2020-12-16 2023-10-25 ABM Therapeutics Corporation Kinase inhibitors and uses thereof
JP2024511476A (ja) 2021-03-27 2024-03-13 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺微生物イソニコチンアミド誘導体
WO2023089049A2 (en) 2021-11-19 2023-05-25 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62223173A (ja) * 1986-03-25 1987-10-01 Otsuka Pharmaceut Factory Inc ピリジルアミノフエノ−ル誘導体及びその製造方法
US4959378A (en) * 1989-10-24 1990-09-25 Hoechst-Roussel Pharmaceuticals Inc. Aminopyridinylaminophenol compounds useful as topical antiinflammatory agents for the treatment of skin disorders
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
JP2002511092A (ja) 1997-07-01 2002-04-09 ワーナー−ランバート・コンパニー ４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用
ES2274572T3 (es) * 1997-07-01 2007-05-16 Warner-Lambert Company Llc Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
KR20010099877A (ko) * 1998-12-22 2001-11-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 배합물 화학요법
EP1150950A2 (en) 1999-01-13 2001-11-07 Warner-Lambert Company Anthranilic acid derivatives
WO2000042003A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
AU2482800A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
AP2001002224A0 (en) 1999-01-13 2001-09-30 Warner Lambert Co Benzoheterocycles and their use as MEK inhibitors.
HUP0105092A3 (en) * 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CA2377100A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
BR0111034A (pt) * 2000-05-22 2003-06-17 Leo Pharma S A Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids
IL153817A0 (en) * 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2002083622A2 (en) * 2001-04-10 2002-10-24 Leo Pharma A/S Novel aminophenyl ketone derivatives
WO2003027107A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
WO2003035626A2 (en) 2001-10-23 2003-05-01 Applied Research Systems Ars Holding N.V. Azole derivatives and pharmaceutical compositions containing them
AR038972A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
PL233493B1 (pl) 2002-03-13 2019-10-31 Array Biopharma Inc Związek benzoimidazolowy, jego zastosowanie oraz zawierająca go kompozycja farmaceutyczna
CA2482345A1 (en) 2002-05-31 2003-12-11 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
WO2004052280A2 (en) * 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US8178570B2 (en) * 2003-04-09 2012-05-15 Exelixis, Inc. Tie-2 modulators and methods of use
PT1802579E (pt) * 2004-10-20 2014-02-17 Merck Serono Sa Derivados da 3-arilaminopiridina
CA2622755C (en) * 2005-10-07 2017-01-31 Exelixis, Inc. Azetidines as mek inhibitors

Also Published As

Publication number Publication date
SI1802579T1 (sl) 2014-03-31
US20120295889A1 (en) 2012-11-22
US20140051686A1 (en) 2014-02-20
UA94571C2 (en) 2011-05-25
US20110224192A1 (en) 2011-09-15
CY1114861T1 (el) 2016-12-14
DK1802579T3 (da) 2014-01-20
AU2005298932B2 (en) 2012-03-22
EP1802579A1 (en) 2007-07-04
MX2007004781A (es) 2007-05-11
JP5214971B2 (ja) 2013-06-19
US8841459B2 (en) 2014-09-23
US8524911B2 (en) 2013-09-03
NO20072595L (no) 2007-06-22
BRPI0518192B8 (pt) 2021-05-25
CA2582247A1 (en) 2006-05-04
KR20070067727A (ko) 2007-06-28
US20090093462A1 (en) 2009-04-09
CN101065358A (zh) 2007-10-31
EA013212B1 (ru) 2010-04-30
PL1802579T3 (pl) 2014-04-30
CN101065358B (zh) 2015-03-11
EP1802579B1 (en) 2013-11-20
EA200700902A1 (ru) 2007-10-26
WO2006045514A1 (en) 2006-05-04
US8198457B2 (en) 2012-06-12
HK1107347A1 (en) 2008-04-03
BRPI0518192A (pt) 2008-11-04
CA2582247C (en) 2014-02-11
ZA200703912B (en) 2008-09-25
JP2008517024A (ja) 2008-05-22
US7956191B2 (en) 2011-06-07
BRPI0518192B1 (pt) 2020-11-24
AU2005298932A1 (en) 2006-05-04
ES2444866T3 (es) 2014-02-27
KR101318012B1 (ko) 2013-10-14
PT1802579E (pt) 2014-02-17
NO339639B1 (no) 2017-01-16

Similar Documents

Publication Publication Date Title
AR051248A1 (es) Derivados de 3-arilamino piridina
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
RU2336275C2 (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция
AR046081A1 (es) Inhibidores heterociclicos de mek y uso de los mismos
AR038971A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR038972A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR045738A1 (es) Derivados de bencimidazol n3 alquilados como inhibidores de mek
RU2007124329A (ru) ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ
AR050180A1 (es) Derivados de guanidina y sus usos terapeuticos
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
MX9204139A (es) Nuevos derivados de bencimidazolona, procedimiento para su preparacion y composicion farmaceutica que los contiene.
AR060316A1 (es) Azaindoles de utilidad como inhibidores de janus quinasas
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR038419A1 (es) Derivados de piridina y quinolina
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
AR044762A1 (es) Derivados de ester y amida del acido 2-cianopropanoico, un proceso para su preparacion y el uso de dichos derivados para la preparacion de un medicamento
RU2009126745A (ru) Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств
AR068045A1 (es) Derivados de catecolamina y prodrogas de los mismos
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
AR038213A1 (es) Esteres hidroxamato del acido n-(4-fenil sustituido)-antranilico
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
MX9204622A (es) Nuevos derivados de 3,5-di-tert-butil-4-hidroxifenilo, procedimiento para su preparacion y composicion farmaceutica que los contiene.
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
PE20040907A1 (es) Derivados de anilinopirazol

Legal Events

Date Code Title Description
FG Grant, registration